Over 16 million Americans with private insurance now lack coverage for GLP-1 weight loss drugs, as insurers quietly restrict access to cutting-edge treatments across healthcare.
Kristi Turner lost 108 pounds on Zepbound. Her blood sugar stabilized, her sleep improved, and she had the energy to keep up with friends on the pickleball court. Then, in January 2025, her insurer cut her off. The reason: she did not have diabetes. Despite being prescribed a drug specifically designed for weight loss, her coverage evaporated without warning. She now pays roughly $500 a month out of pocket to stay on the medication, a sharp climb from her previous $25 copay.
Turner is not an anomaly. As Business Insider recently reported, insurers are systematically tightening access to GLP-1 receptor agonists, a class of drugs that includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound. An analysis by GoodRx found that insurance coverage for these two drugs became significantly more restrictive heading into 2026. The number of people without commercial coverage for Wegovy jumped 42% in a single year, while uncovered Zepbound prescriptions climbed 12%. According to the same analysis, more than 16 million people on employer-based and marketplace plans now have zero coverage for this drug class when prescribed for weight management.
What makes this trend particularly notable is that GLP-1s were never just about weight loss. Originally developed to treat type 2 diabetes, these drugs have shown promise in reducing the severity of sleep apnea, easing osteoarthritis, lowering cardiovascular risk, and even curbing addictive behaviors. Research increasingly suggests that many patients will need to remain on these medications long-term to sustain the benefits. KFF, the nonprofit health research group, estimates that roughly 36 million people enrolled in employer-sponsored insurance plans could clinically qualify for these treatments.
That sheer volume is exactly what spooks payers. GLP-1s carry list prices ranging from roughly $1,000 to $1,350 per month before insurance or manufacturer discounts. When demand surged far beyond initial projections, employers and insurers scrambled to contain costs. Some have added exhaustive step-therapy requirements, demanding that patients complete months of diet counseling, physical therapy, mental health evaluations, and lab work before even reconsidering coverage. Others have simply dropped the drugs from their formularies for non-diabetic patients.
But the retreat extends well beyond obesity drugs. Patients and physicians have reported coverage being scaled back or denied for immunotherapy, mental health services, and fertility treatments like IVF. Amanda Nguyen, a senior health economist at GoodRx, describes the pattern as "coverage with a catch." Increasingly, patients who assumed they were well insured are discovering that their plans exclude the very treatments their doctors recommend.
The Cash-Pay Workaround and Its Limits
One consequence of this coverage gap is a growing consumer shift toward cash payments and pharmacy discount services. Patients are bypassing insurance altogether, shopping aggressively for the lowest prices through online pharmacies, coupon platforms, and direct-to-consumer telehealth providers. Eli Lilly has leaned into this trend by launching its own direct-sales channel for certain GLP-1 products at reduced list prices, explicitly targeting patients whose insurance will not cover the drugs.
This workaround, however, only helps people who can afford to absorb hundreds of dollars in monthly costs. For lower-income patients, the choice is stark: ration medication, switch to less effective alternatives, or abandon treatment entirely. The inequity is hard to ignore. As Turner put it, her husband's type 2 diabetes prescription for Mounjaro remains fully covered with the same $25 copay she once enjoyed. Their insurer will pay for the downstream disease but not the condition that precedes it.
For employers and benefits administrators, this is a slow-burning crisis. Pressure is mounting from workers who expect comprehensive coverage, especially at companies that have marketed generous health benefits as a recruiting tool. Yet pharmacy benefit managers continue to squeeze formularies as drug costs consume a larger share of total health spending. The tension between clinical evidence, patient demand, and budgetary reality shows no sign of resolving cleanly.
The broader signal here matters beyond any single drug class. The gap between what modern medicine can do and what insurers are willing to pay for is widening, and it is reshaping how millions of Americans access care. Watch for employer coalitions to begin negotiating directly with drug manufacturers, and for legislative efforts to mandate broader GLP-1 coverage, to accelerate through 2026. The companies that figure out how to bridge this gap, whether through direct purchasing models, outcome-based pricing, or redesigned benefit structures, will define the next phase of the healthcare cost debate.
